Tetrofosmin

Summary

Tetrofosmin (CHEMBL1615784) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 2
• Chemistry: 382.5 Da · C18H40O4P2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1615784
Name	Tetrofosmin
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	4274
Molecular formula	C18H40O4P2
Molecular weight	382.5
InChIKey	QCWJONLQSHEGEJ-UHFFFAOYSA-N

SMILES: CCOCCP(CCOCC)CCP(CCOCC)CCOCC

IUPAC name: 2-[bis(2-ethoxyethyl)phosphanyl]ethyl-bis(2-ethoxyethyl)phosphane

Also known as: P-53, P53, Tetrofosmin, Tetrofosmina, Tetrofosmine, TETROFOSMIN

Patent coverage: 824 distinct patent families (3,047 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03467308	Not specified	COMPLETED	Signaling Pathways Targeting Colorectal Cancer in Egypt
NCT05269901	Not specified	COMPLETED	Association Between Ferroptosis and Epilepsy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).